scholarly journals Immunohistochemical analysis of S-100 protein-positive dendritic cells in human cutaneous squamous cell carcinomas, Bowen's diseases and basal cell carcinomas.

1992 ◽  
Vol 32 (4) ◽  
pp. 349-358
Author(s):  
Yuiko Manabe ◽  
Yuji Ohtsuki
2012 ◽  
Vol 87 (2) ◽  
pp. 212-219 ◽  
Author(s):  
Pedro Andrade ◽  
Maria Manuel Brites ◽  
Ricardo Vieira ◽  
Angelina Mariano ◽  
José Pedro Reis ◽  
...  

BACKGROUND: Non-melanoma skin cancer, a common designation for both basal cell carcinomas and squamous cell carcinomas, is the most frequent malignant skin neoplasm. OBJECTIVE: Epidemiologic characterization of the population with Non-melanoma skin cancer. METHODS: Retrospective analysis of all patients diagnosed with Non-melanoma skin cancer based on histopathologic analysis of all incisional or excisional skin biopsies performed between 2004 and 2008 in a Department of Dermatology. RESULTS: A total of 3075 Non-melanoma skin cancers were identified, representing 88% of all malignant skin neoplasms (n=3493) diagnosed in the same period. Of those, 68,3% were basal cell carcinomas. Most Non-melanoma skin cancer patients were female and over 60 years old. Of all Non-melanoma skin cancer, 81,7% (n=1443) were located in sun-exposed skin, and represented 95,1% of malignant skin neoplasms in sun-exposed skin. Non-melanoma skin cancer was the most frequent malignant skin neoplasm in most topographic locations, except for abdomen and pelvis - over 95% of all malignant skin neoplasms in the face, neck and scalp were Non-melanoma skin cancer. Basal cell carcinomas were clearly predominant in all locations, except in upper and lower limbs, lower lip and genitals, where squamous cell carcinomas represented respectively 77,7%, 77,4%, 94,7% and 95,3% of the Non-melanoma skin cancers. CONCLUSION: Being the most common skin cancer, Non-melanoma skin cancer should be under constant surveillance, in order to monitor its epidemiologic dynamics, the efficiency of preventive measures and the adaptation of the healthcare resources.


2013 ◽  
Vol 23 (1) ◽  
pp. 83-86 ◽  
Author(s):  
Roberto Betti ◽  
Carlo Crosti ◽  
Simona Ghiozzi ◽  
Amilcare Cerri ◽  
Laura Moneghini ◽  
...  

2020 ◽  
Vol 15 (12) ◽  
pp. 1804-1813
Author(s):  
Thibault Letellier ◽  
Florent Leborgne ◽  
Clarisse Kerleau ◽  
Aurélie Gaultier ◽  
Jacques Dantal ◽  
...  

Background and objectivesKeratinocyte cancers, which primarily comprise squamous cell carcinomas and basal cell carcinomas, represent a major concern and potential risk for kidney transplant recipients. Hydrochlorothiazide, a diuretic widely used to treat hypertension, has been implicated in skin photosensitivity reaction. Recent studies conducted in the general population have found that hydrochlorothiazide use is associated with a higher risk of keratinocyte cancer, especially squamous cell carcinomas. High-risk groups, however, including transplant recipients were excluded from these. Our aim was to investigate whether hydrochlorothiazide use was associated with keratinocyte cancer in kidney transplant recipients on immunosuppressive therapy.Design, setting, participants, & measurementsIn a single-center cohort of kidney (n=2155), combined kidney-pancreas (n=282), and pancreas (n=59) transplant recipients from the Données Informatisées VAlidées Transplantation (DIVAT) database transplanted between 2000 and 2017 in Nantes, France, we evaluated the association between hydrochlorothiazide exposure and keratinocyte cancers. Multivariable cause-specific, time-varying Cox models were used to estimate the relationship between hydrochlorothiazide exposure and the hazard of squamous cell carcinoma and basal cell carcinoma, with hydrochlorothiazide designated as the time-dependent variable.ResultsAmong the participants, 279 of 2496 (11%) were exposed to hydrochlorothiazide after the transplantation. Cumulative incidence rates of keratinocyte cancer by 10 and 15 years were 7% and 9% for squamous cell carcinomas, respectively, and 8% and 11% for basal cell carcinomas, respectively. We found a relationship between exposure to hydrochlorothiazide and the risk of squamous cell carcinomas (hazard ratio, 2.04; 95% confidence interval, 1.27 to 3.28). In contrast, we found no association between hydrochlorothiazide exposure and basal cell carcinomas (hazard ratio, 0.63; 95% confidence interval, 0.35 to 1.15).ConclusionsIn a single-center cohort of kidney, combined kidney-pancreas, and pancreas transplant recipients, exposure to hydrochlorothiazide was associated with a two-fold higher risk of squamous cell carcinoma and no higher risk of basal cell carcinoma.


2000 ◽  
Vol 62 (7) ◽  
pp. 743-750 ◽  
Author(s):  
Yuichi MURAKAMI ◽  
Susumu TATEYAMA ◽  
Anudep RUNGSIPIPAT ◽  
Kazuyuki UCHIDA ◽  
Ryoji YAMAGUCHI

Sign in / Sign up

Export Citation Format

Share Document